November 13, 2012 // by Lene Andersen
Really great news in RA treatment! I wrote about the new drug in more detail on HealthCentral: “Last week, the FDA approved a new drug to treat moderate to severe RA. Pfizer’s Xeljanz – brand-name tofacitinib – is the first in a new class of medications called Janus kinase (JAK) inhibitors. It is also the…
Category: HealthCentral
Tag:
How we use cookies
We use some essential cookies to make this website work. We'd like to set additional cookies to provide social media features, to analyse our traffic, and to remember your settings and repeat visits. By selecting “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
| Cookie | Duration | Description |
|---|---|---|
| cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
| cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
| cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
| cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
| cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
| viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |